These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29762046)

  • 1. Effects of calcimimetics on long-term outcomes in dialysis patients: literature review and Bayesian meta-analysis.
    Lozano-Ortega G; Waser N; Bensink ME; Goring S; Bennett H; Block GA; Chertow GM; Trotman ML; Cooper K; Levy AR; Belozeroff V
    J Comp Eff Res; 2018 Jul; 7(7):693-707. PubMed ID: 29762046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet plus vitamin D versus vitamin D alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials.
    Xu J; Yang Y; Ma L; Fu P; Peng H
    Int Urol Nephrol; 2019 Nov; 51(11):2027-2036. PubMed ID: 31531805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinacalcet Treatment Significantly Improves All-Cause and Cardiovascular Survival in Dialysis Patients: Results from a Meta-Analysis.
    Zu Y; Lu X; Song J; Yu L; Li H; Wang S
    Kidney Blood Press Res; 2019; 44(6):1327-1338. PubMed ID: 31747666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.
    Warady BA; Ng E; Bloss L; Mo M; Schaefer F; Bacchetta J
    Pediatr Nephrol; 2020 Sep; 35(9):1679-1697. PubMed ID: 32367309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis.
    Sekercioglu N; Busse JW; Sekercioglu MF; Agarwal A; Shaikh S; Lopes LC; Mustafa RA; Guyatt GH; Thabane L
    Ren Fail; 2016 Jul; 38(6):857-74. PubMed ID: 27137817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
    Drüeke TB
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
    Parfrey PS; Drüeke TB; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Kubo Y; Dehmel B; Goodman WG; Chertow GM;
    Clin J Am Soc Nephrol; 2015 May; 10(5):791-9. PubMed ID: 25710802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of cinacalcet withdrawal in Australian dialysis patients.
    Ruderman I; Holt SG; Kirkland GS; Maslen S; Hawley CM; Oliver V; Krishnasamy R; Gray NA; Talaulikar GS; Nelson CL; Rajaram Y; Gock H; Au E; Elder GJ; Mainra R; Toussaint ND
    Intern Med J; 2019 Jan; 49(1):48-54. PubMed ID: 29992701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism.
    Ruderman I; Smith ER; Toussaint ND; Hewitson TD; Holt SG
    BMC Nephrol; 2018 May; 19(1):113. PubMed ID: 29764395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis.
    Chen L; Wang K; Yu S; Lai L; Zhang X; Yuan J; Duan W
    Ren Fail; 2016 Aug; 38(7):1050-8. PubMed ID: 27198474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis.
    Wang G; Liu H; Wang C; Ji X; Gu W; Mu Y
    Sci Rep; 2018 Feb; 8(1):3111. PubMed ID: 29449603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis.
    Zhang Q; Li M; You L; Li H; Ni L; Gu Y; Hao C; Chen J
    PLoS One; 2012; 7(10):e48070. PubMed ID: 23133549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.
    Cunningham J; Danese M; Olson K; Klassen P; Chertow GM
    Kidney Int; 2005 Oct; 68(4):1793-800. PubMed ID: 16164656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parathyroidectomy versus oral cinacalcet on cardiovascular parameters in peritoneal dialysis patients with advanced secondary hyperparathyroidism (PROCEED): a randomized trial.
    Wang AY; Lo WK; Cheung SC; Tang TK; Yau YY; Lang BH
    Nephrol Dial Transplant; 2023 Jul; 38(8):1823-1835. PubMed ID: 36869794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortality.
    Gillespie IA; Floege J; Gioni I; Drüeke TB; de Francisco AL; Anker SD; Kubo Y; Wheeler DC; Froissart M;
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):738-47. PubMed ID: 26011775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
    Strippoli GF; Tong A; Palmer SC; Elder G; Craig JC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD006254. PubMed ID: 17054287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.
    Wheeler DC; London GM; Parfrey PS; Block GA; Correa-Rotter R; Dehmel B; Drüeke TB; Floege J; Kubo Y; Mahaffey KW; Goodman WG; Moe SM; Trotman ML; Abdalla S; Chertow GM; Herzog CA;
    J Am Heart Assoc; 2014 Nov; 3(6):e001363. PubMed ID: 25404192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.
    Akizawa T; Kurita N; Mizobuchi M; Fukagawa M; Onishi Y; Yamaguchi T; Ellis AR; Fukuma S; Alan Brookhart M; Hasegawa T; Kurokawa K; Fukuhara S
    Sci Rep; 2016 Apr; 6():19612. PubMed ID: 27071541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.